<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223701</url>
  </required_header>
  <id_info>
    <org_study_id>CR-17-101</org_study_id>
    <nct_id>NCT03223701</nct_id>
  </id_info>
  <brief_title>Efficacy of Using Solum IV and BMC With GFC in TLIF</brief_title>
  <official_title>Efficacy Study Using Solum IV, Bone Marrow Concentrate With General Fluid Concentrate in Transforaminal Lumbar Interbody Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seton Healthcare Family</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celling Biosciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seton Healthcare Family</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy of using Solum IV and bone marrow&#xD;
      concentrate with general fluid concentrate in Transforaminal Lumbar Interbody Fusion (TLIF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-center clinical study. Ten patients will be enrolled and&#xD;
      undergo an TLIF with a spinal fixation system and receive Solum IV (Celling Biosciences) and&#xD;
      patient's BMC with GFC.&#xD;
&#xD;
      The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects.&#xD;
      The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences,&#xD;
      Austin, TX) platform technology to obtain the BMC preparation. The plasma component that&#xD;
      remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus&#xD;
      device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled&#xD;
      subjects' BMC and GFC will be provided to the principle investigator who will combine the two&#xD;
      together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF&#xD;
      procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive&#xD;
      lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the&#xD;
      interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle&#xD;
      screw system (Xia 3 system).&#xD;
&#xD;
      All study subjects will be assessed for fusion rate, complication rates and subject-reported&#xD;
      outcomes at designated intervals up to 12 months after surgery. X-rays (anterior-posterior,&#xD;
      lateral, flexion-extension) will be taken at pre-operatively, 3, 6, and 12 months&#xD;
      post-treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was never initiated due to contracting issues&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 30, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a prospective, single-center clinical study. Ten patients will be enrolled and undergo an Transforaminal Lumbar Interbody Fusion (TLIF) with a spinal fixation system and receive Solum IV (Celling Biosciences) and patient's bone marrow concentrate with general fluid concentrate (GFC).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiological assessment : Fusion Status</measure>
    <time_frame>3 months post-treatment</time_frame>
    <description>X-rays (anterior-posterior, lateral, flexion-extension)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological assessment : Fusion Status</measure>
    <time_frame>6 months post-treatment</time_frame>
    <description>X-rays (anterior-posterior, lateral, flexion-extension)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological assessment : Fusion Status</measure>
    <time_frame>12 months post-treatment</time_frame>
    <description>X-rays (anterior-posterior, lateral, flexion-extension)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>Pre-treatment</time_frame>
    <description>Patient reported pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>3 months post-treatment</time_frame>
    <description>Patient reported pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>6 months post-treatment</time_frame>
    <description>Patient reported pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>12 months post-treatment</time_frame>
    <description>Patient reported pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>Pre-treatment</time_frame>
    <description>Patient reported disability score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>3 months post-treatment</time_frame>
    <description>Patient reported disability score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>6 months post-treatment</time_frame>
    <description>Patient reported disability score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>12 months post-treatment</time_frame>
    <description>Patient reported disability score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Isthmic-lytic Spondylolisthesis</condition>
  <condition>Degenerative Spondylolisthesis</condition>
  <condition>Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The group will consist of 10 patients who would be examined for fusion rates of Transforaminal Lumbar Interbody Fusion with a standalone lumbar implant device and Solum IV and the patient's bone marrow concentrate and general fluid concentrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion</intervention_name>
    <description>The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is skeletally mature and older than 18 years of age&#xD;
&#xD;
          2. One and contiguous 2 or 3 level primary lumbar fusions.&#xD;
&#xD;
          3. L1 to S1 with a primary diagnosis of one or more of the following:&#xD;
&#xD;
               1. Degenerative disc disease,&#xD;
&#xD;
               2. Isthmic-lytic spondylolisthesis,&#xD;
&#xD;
               3. Degenerative spondylolisthesis&#xD;
&#xD;
               4. Spinal stenosis.&#xD;
&#xD;
          4. Subject has received conservative (non -surgical treatment for back pain for a minimum&#xD;
             of 6 months and is unresponsive&#xD;
&#xD;
          5. Subject understand the conditions of enrollment and is willing to sign and date the&#xD;
             informed consent form&#xD;
&#xD;
          6. Subject agrees to comply with study visits&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous bilateral Iliac Crest Bone Graft (ICBG) harvest&#xD;
&#xD;
          2. Previous instrumented fusion at the same or adjacent level&#xD;
&#xD;
          3. Active systemic infection, infection localized to the site of implantation or at&#xD;
             aspiration site&#xD;
&#xD;
          4. Vulnerable patients&#xD;
&#xD;
               1. Nursing home residents&#xD;
&#xD;
               2. Prisoners&#xD;
&#xD;
               3. Other institutionalized persons&#xD;
&#xD;
               4. Persons with decisional incapacity&#xD;
&#xD;
          5. Pregnant women or interested in becoming pregnant in the next 12 months&#xD;
&#xD;
          6. Subjects with certain autoimmune diseases (such as lupus)&#xD;
&#xD;
          7. Subject has progressive neuromuscular disease&#xD;
&#xD;
          8. Active hepatitis, AIDS, ARS or is HIV positive&#xD;
&#xD;
          9. Syringomyelia at any spinal levels&#xD;
&#xD;
         10. Any other condition that would interfere with the subject self-assessment of pain,&#xD;
             function or quality of life&#xD;
&#xD;
         11. Subjects with multiple allergies&#xD;
&#xD;
         12. Subjects with any history of cancer (except for basal cell carcinoma of the skin)&#xD;
&#xD;
         13. Significant osteoporosis&#xD;
&#xD;
         14. Subject is younger than or equal to 18 years of age&#xD;
&#xD;
         15. Subjects with a BMI of 40 or greater&#xD;
&#xD;
         16. Subject has diabetes mellitus requiring daily insulin management&#xD;
&#xD;
         17. Subject has allergy to implant materials (such as titanium, titanium alloy)&#xD;
&#xD;
         18. Subject has primary or metastatic tumors involving the spine&#xD;
&#xD;
         19. Subject is participating in another investigational study for a similar purpose&#xD;
&#xD;
         20. Subject has a history of significant mental illness or mental incapacity&#xD;
&#xD;
         21. Subject is currently smoker and will not cease smoking from the time of study&#xD;
             enrollment up through 3 months post-operatively, nicotine users for whom&#xD;
             post-operative bone stimulation would be prescribed, or has a recent history of&#xD;
             alcohol or other substance abuse within the past 2 years&#xD;
&#xD;
         22. Subject is receiving workers compensation&#xD;
&#xD;
         23. Absence of English language reading or writing skills&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eeric Truumees, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seton Spine and Scoliosis Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seton Spine and Scoliosis Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res. 2002 Dec;(405):14-23.</citation>
    <PMID>12461352</PMID>
  </reference>
  <reference>
    <citation>Gan Y, Dai K, Zhang P, Tang T, Zhu Z, Lu J. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials. 2008 Oct;29(29):3973-82. doi: 10.1016/j.biomaterials.2008.06.026. Epub 2008 Jul 18.</citation>
    <PMID>18639333</PMID>
  </reference>
  <reference>
    <citation>Galois L, Bensoussan D, Diligent J, Pinzano A, Henrionnet C, Choufani E, Stoltz JF, Mainard D. Autologous bone marrow graft and treatment of delayed and non-unions of long bones: technical aspects. Biomed Mater Eng. 2009;19(4-5):277-81. doi: 10.3233/BME-2009-0592.</citation>
    <PMID>20042794</PMID>
  </reference>
  <reference>
    <citation>Johnson RG. Bone marrow concentrate with allograft equivalent to autograft in lumbar fusions. Spine (Phila Pa 1976). 2014 Apr 20;39(9):695-700. doi: 10.1097/BRS.0000000000000254.</citation>
    <PMID>24503679</PMID>
  </reference>
  <results_reference>
    <citation>Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am. 2005 Jul;87(7):1430-7.</citation>
    <PMID>15995108</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

